


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31200322</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0852</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>116</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>11</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of cancer (Oxford, England : 1990)</Title>
                <ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>158-168</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0959-8049(19)30310-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2019.05.007</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Plasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. However, the relevance of plasma AR status in the context of cabazitaxel therapy is unknown.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Between September 2011 and January 2018, pretherapy plasma samples were collected from 155 patients treated with second- or third-line cabazitaxel at standard or reduced dose in different biomarker protocols. Droplet digital polymerase chain reaction was used to identify plasma AR gain and normal samples. The primary objective was to evaluate associations of plasma AR status with treatment outcome. In an exploratory analysis, a comparison between plasma AR and treatment type was investigated by incorporating updated data from our prior study of 85 post-docetaxel patients receiving abiraterone or enzalutamide.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed a shorter median overall survival (OS) and progression-free survival (PFS) in AR-gained compared to AR-normal patients (OS 10.5 versus 14.1 months, hazard ratio (HR) = 1.44, 95% confidence interval [CI] 0.98-2.13, P = 0.064 and PFS 4.0 versus 5.0 months, HR = 1.47, 95% CI 1.05-2.07, P = 0.024). In patients with mCRPC receiving second-line therapies, a significant treatment interaction was observed between plasma AR and cabazitaxel versus AR-directed therapies for OS (P = 0.041) but not PFS (P = 0.244). In an exploratory analysis, AR-gained patients treated with initial reduced dose of cabazitaxel had a significantly shorter median OS (7.3 versus 11.5 months, HR = 1.95, 95% CI 1.13-3.38, P = 0.016) and PFS (2.7 versus 5.0 months, HR = 2.27, 95% CI 1.39-3.71, P = 0.001).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Plasma AR status has a potential clinical utility in patients being considered for cabazitaxel. Validation of these findings in prospective trials is warranted.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Conteduca</LastName>
                    <ForeName>Vincenza</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto Scientifico Romagnolo per Io Studio e La Cura dei Tumori (IRST) IRCCS, Meldola, Italy; University College London Cancer Institute, London, UK. Electronic address: vincenza.conteduca@irst.emr.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castro</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Hospital Universitario Quirón, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wetterskog</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>University College London Cancer Institute, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scarpi</LastName>
                    <ForeName>Emanuela</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto Scientifico Romagnolo per Io Studio e La Cura dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jayaram</LastName>
                    <ForeName>Anuradha</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University College London Cancer Institute, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Romero-Laorden</LastName>
                    <ForeName>Nuria</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olmos</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de Ia Victoria y Regional de Málaga, Instituto de Investigación Biomédica de Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gurioli</LastName>
                    <ForeName>Giorgia</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto Scientifico Romagnolo per Io Studio e La Cura dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lolli</LastName>
                    <ForeName>Cristian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto Scientifico Romagnolo per Io Studio e La Cura dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sáez</LastName>
                    <ForeName>Maria Isabel</ForeName>
                    <Initials>MI</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de Ia Victoria y Regional de Málaga, Instituto de Investigación Biomédica de Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puente</LastName>
                    <ForeName>Javier</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schepisi</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto Scientifico Romagnolo per Io Studio e La Cura dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salvi</LastName>
                    <ForeName>Samanta</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto Scientifico Romagnolo per Io Studio e La Cura dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wingate</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University College London Cancer Institute, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Medina</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Centro Oncológico de Galicia, A Coruña, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Querol-Niñerola</LastName>
                    <ForeName>Rosa</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital de Mataró, Mataró, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marin-Aguilera</LastName>
                    <ForeName>Mercedes</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, IDIBAPS, Hospital Clínico y Provincial, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arranz</LastName>
                    <ForeName>Jose Angel</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Gregorio Marañón University Hospital, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fornarini</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Basso</LastName>
                    <ForeName>Umberto</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mellado</LastName>
                    <ForeName>Begoña</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, IDIBAPS, Hospital Clínico y Provincial, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonzalez-Billalabeitia</LastName>
                    <ForeName>Enrique</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology &amp; Medical Oncology, Hospital Universitario Morales Meseguer, IMIB-Universidad de Murcia, Murcia, Spain; Universidad Católica San Antonio de Murcia-UCAM, Murcia, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Attard</LastName>
                    <ForeName>Gerhardt</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>University College London Cancer Institute, London, UK. Electronic address: g.attard@ucl.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Giorgi</LastName>
                    <ForeName>Ugo</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto Scientifico Romagnolo per Io Studio e La Cura dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Cancer</MedlineTA>
            <NlmUniqueID>9005373</NlmUniqueID>
            <ISSNLinking>0959-8049</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AR-directed therapies</Keyword>
            <Keyword MajorTopicYN="N">Androgen receptor</Keyword>
            <Keyword MajorTopicYN="N">Biomarker</Keyword>
            <Keyword MajorTopicYN="N">Cabazitaxel</Keyword>
            <Keyword MajorTopicYN="N">Castration-resistant prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Plasma DNA</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31200322</ArticleId>
            <ArticleId IdType="pii">S0959-8049(19)30310-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.05.007</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

